Newsroom 

Dr Anita Kale, Senior Consultant, Division of Maternal Fetal Medicine, Department of Obstetrics & Gynaecology, NUH, said the maternal RSV vaccine is now part of routine antenatal discussions and is offered from 32 weeks of pregnancy. However, uptake remains insufficient to reduce infant hospitalisations. Dr Chan Si Min, Head of Division & Senior Consultant, Division of Paediatric Infectious Diseases, Department of Paediatrics, KTP-NUCMI, NUH, noted that RSV-related admissions and bronchiolitis cases among infants have remained stable since the vaccine’s introduction in 2024, with a small number requiring intensive care each month. She added that longer-term data and higher uptake will be needed to reduce severe RSV disease in infants.